APIM Therapeutics
closedImproving Chemotherapy for Cancer Patients.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | NOK25.0m | Early VC | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
APIM Therapeutics AS is a venture capital-backed biotech company originating from the Norwegian University of Science and Technology (NTNU) in Trondheim. The company focuses on developing innovative peptide drugs that target PCNA-dependent stress responses in cancer cells, a critical factor in tumor resistance to therapy. Their lead drug candidate, ATX 101, is currently undergoing phase I clinical trials in patients with advanced cancer. APIM Therapeutics operates in the oncology market, primarily serving patients with treatment-resistant cancers. The company's business model revolves around the research and development of novel therapeutic drugs, with revenue generated through venture capital funding and potential future sales or licensing agreements.
Keywords: peptide drugs, cancer therapy, PCNA, stress responses, oncology, biotech, phase I trials, tumor resistance, therapeutic intervention, venture capital.